GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Capex-to-Revenue

Akums Drugs and Pharmaceuticals (NSE:AKUMS) Capex-to-Revenue : 0.07 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Akums Drugs and Pharmaceuticals's Capital Expenditure for the six months ended in Sep. 2024 was ₹-1,503.62 Mil. Its Revenue for the six months ended in Sep. 2024 was ₹20,522.00 Mil.

Hence, Akums Drugs and Pharmaceuticals's Capex-to-Revenue for the six months ended in Sep. 2024 was 0.07.

Akums Drugs and Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals Capex-to-Revenue Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
0.03 0.07 0.10 0.08

Akums Drugs and Pharmaceuticals Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial 0.12 0.07 0.06 0.09 0.07

Competitive Comparison of Akums Drugs and Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akums Drugs and Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's Capex-to-Revenue falls into.


Akums Drugs and Pharmaceuticals Capex-to-Revenue Calculation

Akums Drugs and Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3114.08) / 40196.82
=0.08

Akums Drugs and Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1503.62) / 20522
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Akums Drugs and Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » Capex-to-Revenue
Comparable Companies
BOM:543748 BOM:530549 BOM:531599 BOM:500126 NSE:STAR BOM:506690 BOM:524372 NSE:INNOVACAP BOM:524735 BOM:532872 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
544222:India
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Website
https://www.akums.in
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines